bioMerieux (FR:BIM)
:BIM
Want to see FR:BIM full AI Analyst Report?
Top Page
bioMerieux
(BIM)
Select Model
Select Model
Rating:61Neutral
Price Target:
€74.00
▼(-18.90% Downside)
Action:ReiteratedDate:04/29/26
The score is supported mainly by strong underlying financial stability (low leverage, solid margins, improved 2025 free cash flow), but is meaningfully weighed down by very weak technicals (price far below major moving averages with bearish MACD) and a relatively expensive valuation (P/E ~32.7 with only ~1.29% yield).
Positive Factors
Conservative balance sheet and low leverage
Low net leverage and a large equity base provide durable financial flexibility: the company can fund R&D, platform placements, and absorb cyclical softness without forced asset sales. This structural strength reduces solvency risk and supports long-term capital allocation choices across 2–6 months and beyond.
Negative Factors
Softening revenue and profitability trends
A reversal from prior growth and peak margins reduces operating leverage and constrains reinvestment capacity. Persistent or renewed revenue decline would weaken consumable pull-through and pressure margin sustainability, making medium-term topline recovery critical to preserve durable earnings power.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet and low leverage
Low net leverage and a large equity base provide durable financial flexibility: the company can fund R&D, platform placements, and absorb cyclical softness without forced asset sales. This structural strength reduces solvency risk and supports long-term capital allocation choices across 2–6 months and beyond.
Read all positive factors
bioMerieux (BIM) vs. iShares MSCI France ETF (EWQ)
Market Cap
€8.47B
Dividend Yield0.82%
Average Volume (3M)107.98K
Price to Earnings (P/E)32.7
Beta (1Y)0.67
Revenue Growth2.26%
EPS Growth-8.10%
CountryFR
Employees14,147
SectorGeneral
Sector StrengthN/A
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)2.00
Shares Outstanding118,361,220
10 Day Avg. Volume122,242
30 Day Avg. Volume107,982
Financial Highlights & Ratios
PEG Ratio-4.00
Price to Book (P/B)3.17
Price to Sales (P/S)3.20
P/FCF Ratio28.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€96.77Price Target Upside6.05% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)4.57
Revenue Forecast (FY)€4.15B
bioMerieux Business Overview & Revenue Model
Company Description
bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems, which use biological samples to diagno...
How the Company Makes Money
bioMérieux makes money primarily by selling diagnostic instruments and, more importantly, recurring consumables used on those instruments. Key revenue streams include: (1) Consumables and reagents (recurring): test kits, cartridges, culture media,...
bioMerieux Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
84
Very Positive
Cash Flow
74
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.07B | 3.98B | 3.67B | 3.59B | 3.38B |
| Gross Profit | 2.14B | 2.22B | 2.06B | 1.96B | 1.97B |
| EBITDA | 999.60M | 897.50M | 701.30M | 811.90M | 977.80M |
| Net Income | 397.50M | 432.20M | 357.60M | 452.40M | 601.10M |
Balance Sheet | |||||
| Total Assets | 5.57B | 5.77B | 5.26B | 5.19B | 4.61B |
| Cash, Cash Equivalents and Short-Term Investments | 569.80M | 449.80M | 352.40M | 552.60M | 803.50M |
| Total Debt | 461.40M | 490.70M | 518.80M | 505.40M | 462.50M |
| Total Liabilities | 1.47B | 1.56B | 1.51B | 1.54B | 1.44B |
| Stockholders Equity | 4.10B | 4.20B | 3.75B | 3.60B | 3.11B |
Cash Flow | |||||
| Free Cash Flow | 453.00M | 321.50M | 107.10M | 188.40M | 534.60M |
| Operating Cash Flow | 788.30M | 667.30M | 445.40M | 475.10M | 824.70M |
| Investing Cash Flow | -461.70M | -359.80M | -488.80M | -528.10M | -307.30M |
| Financing Cash Flow | -155.40M | -212.60M | -122.30M | -244.20M | -140.60M |
bioMerieux Technical Analysis
Negative
91.25
Price Trends
93.51
Negative
100.05
Negative
108.23
Negative
Market Momentum
-0.85
Negative
46.05
Neutral
52.88
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:BIM, the sentiment is Negative. The current price of 91.25 is above the 20-day moving average (MA) of 91.12, below the 50-day MA of 93.51, and below the 200-day MA of 108.23, indicating a neutral trend. The MACD of -0.85 indicates Negative momentum. The RSI at 46.05 is Neutral, neither overbought nor oversold. The STOCH value of 52.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:BIM.
bioMerieux Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | €3.11B | 19.88 | 12.62% | 0.41% | 4.82% | 3.80% | |
61 Neutral | €8.47B | 32.73 | 9.69% | 0.82% | 2.26% | -8.10% | |
56 Neutral | €15.25B | 45.89 | 6.65% | 0.31% | 4.43% | 31.23% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | €10.39B | 23.65 | 11.27% | 0.97% | 4.96% | 23.85% |
* General Sector Average
FR:BIM
bioMerieux
71.70
-45.63
-38.89%
FR:ERF
Eurofins Scientific
59.02
2.00
3.50%
FR:DIM
Sartorius Stedim Biotech
156.70
-55.64
-26.20%
FR:VIRP
Virbac SA
371.50
60.50
19.46%
FR:ALECR
Eurofins-Cerep SA
15,900.00
-4,700.00
-22.82%
FR:ALBIO
Biosynex SA
0.81
-0.46
-36.37%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.